Major Pharmaceuticals Recalls Enalapril Maleate Tablets Due to Impurities
Major Pharmaceuticals is recalling specific lots of Enalapril Maleate Tablets, 2.5 mg, because the product failed impurity specifications for a degradation product.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is not likely to cause adverse health consequences. The hazard involves failed impurity specifications without reported illnesses, fitting the criteria for a moderate severity score.
Plain-English summary
Major Pharmaceuticals is recalling 3,397 cartons of Enalapril Maleate Tablets, USP, 2.5 mg. The product is distributed nationwide in the USA and Puerto Rico. The recall is a sub-recall initiated because the manufacturing firm, Wockhardt, identified out-of-specification results for the Enalapril DiKetopiperazine degradation product.
The affected lots are T-01083 (Exp 08/18), DR10447A (Exp 09/18), DS10201A (Exp 07/19), DS10201B (Exp 08/19), DS10201C (Exp 08/19), and DS10319A (Exp 10/19). The tablets are manufactured by Wockhardt Limited and distributed by Wockhardt USA LLC and Major Pharmaceuticals.
Consumers should check their medication for these specific lot numbers and expiration dates. If the product matches the recalled description, they should stop using it and contact their healthcare provider or pharmacist for guidance on obtaining a replacement.
The recalled product
- Product
- Enalapril Maleate Tablets, USP, 2.5 mg, 100 Tablets (10 x 10) Unit Dose per carton, Rx only, Manufactured by: Wockhardt Limited, H-14/2, M.I.D.C. Area, Waluj, Aurangabad, Maharashtra, India; Distributed by: Wockhardt USA LLC., 20 Waterview Blvd., Parsippany, NJ 07054; Distribute
- Manufacturer
- MAJOR PHARMACEUTICALS
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 3,397
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (11)
- Lot #: T-01083
- Exp 08/18
- DR10447A
- Exp 09/18
- DS10201A
- Exp 07/19
- DS10201B
- DS10201C
- Exp 08/19
- DS10319A
- Exp 10/19.
Distribution
Part of a larger recall action
This product is one of 2 recalled by MAJOR PHARMACEUTICALS under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · MAJOR PHARMACEUTICALS
See all →- HighLevothyroxine Sodium Tablets Recalled for Subpotency by Major Pharmaceuticals
FDA (Drugs) · 2026-07-29
- HighLevothyroxine Sodium Tablets Recalled Due to Subpotent Drug Concerns
FDA (Drugs) · 2026-07-29
- SevereLevothyroxine Sodium Tablets Recalled for Subpotency Nationwide
FDA (Drugs) · 2026-07-29
- HighLevothyroxine Sodium Tablets Recalled Due to Subpotent Drug Concerns
FDA (Drugs) · 2026-07-29
- SevereLevothyroxine Sodium Tablets Recalled for Subpotency
FDA (Drugs) · 2026-07-29
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08